Aims: Evaluation of blood pressure in the first year of life in children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. Methods: Twenty-four children were included. Retrospective blood pressure values, fludrocortisone dosages, and serum renin, 17-hydroxyprogesterone (17-OHP) and androstenedione levels in the first year of life were evaluated. Blood pressure values were compared to reference values. Correlations between blood pressures and serum renin levels, and the dosage of fludrocortisone were calculated. Results: Mean peak systolic blood pressure values were generally not elevated, most values were around the 50th percentile, except incidentally higher mean peak systolic blood pressure values most below the 95th percentile. No significant correlations between blood pressure and serum renin, androstenedione and 17-OHP levels and fludrocortisone dosage were found. Conclusion: In this pilot studyin CAH patients, blood pressure values do not seem to be elevated in the first year of life. Further investigations are necessary to evaluate blood pressure in the first year of life in CAH patients in more detail.

Keywords:
Congenital adrenal hyperplasia, Neonates, Hypertension
1.
Speiser PW, White PC: Congenital adrenal hyperplasia. N Engl J Med 2003;349:776–788.
2.
White PC, Speiser PW: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000;21:245–291.
3.
Charmandari E, Chrousos GP: Metabolic syndrome manifestations in classic congenital adrenal hyperplasia: do they predispose to atherosclerotic cardiovascular disease and secondary polycystic ovary syndrome? Ann NY Acad Sci 2006;1083:37–53.
4.
de Silva KS, Kanumakala S, Brown JJ, Jones CL, Warne GL: 24-hour ambulatory blood pressure profile in patients with congenital adrenal hyperplasia – a preliminary report. J Pediatr Endocrinol Metab 2004;17:1089–1095.
5.
Roche EF, Charmandari E, Dattani MT, Hindmarsh PC: Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydrocylase deficiency): a preliminary report. Clin Endocrinol 2003;58:589–596.
6.
Völkl TMK, Simm D, Dötsch J, Rascher W, Dörr HG: Altered 24-hour blood pressure profiles in children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006;91:4888–4895.
7.
Hoepffner W, Herrmann A, Willgerodt H, Keller E: Blood pressure in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Pediatr Endocrinol Metab 2006;19:705–711.
8.
Nebesio TD, Eugster EA: Observation of hypertension in children with 21-hydroxylase deficiency: a preliminary report. Endocrine 2006;30:279–282.
9.
Higashi Y, Yoshioka H, Yamane M, Gotoh O, Fujii-Kuriyama Y: Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: a pseudogene an a genuine gene. Proc Natl Acad Sci USA 1986;83:2841–2845.
10.
Report of the Second Task Force on Blood Pressure Control in Children – 1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. Paediatrics 1987;79:1–25.
11.
Flynn JT: Neonatal hypertension: diagnosis and management. Pediatr Nephrol 2000;14:332–341.
12.
Fuller PJ, Young MJ: Mechanisms of mineralocorticoid action. Hypertension 2005;46:1227–1235.
13.
Frey FJ, Odermatt A, Frey BM: Glucocorticoid-mediated mineralocorticoid activation and hypertension. Curr Opini Nephrol Hypertens 2004;13:451–458.
14.
Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab 2006;20:337–353.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.